UK markets close in 7 hours 44 minutes
  • FTSE 100

    +21.30 (+0.29%)
  • FTSE 250

    -32.04 (-0.16%)
  • AIM

    -0.33 (-0.04%)

    +0.0008 (+0.07%)

    -0.0025 (-0.20%)

    -566.74 (-2.80%)
  • CMC Crypto 200

    -6.25 (-1.09%)
  • S&P 500

    -2.97 (-0.07%)
  • DOW

    +27.16 (+0.08%)

    -0.01 (-0.01%)

    -2.30 (-0.13%)
  • NIKKEI 225

    +727.65 (+2.62%)

    +58.86 (+0.29%)
  • DAX

    +63.43 (+0.46%)
  • CAC 40

    +27.65 (+0.42%)

LAMEA Idiopathic Pulmonary Fibrosis Market Report 2022: Featuring Key Players GNI Group, AstraZeneca, Bristol Myers Squibb & Others

·3-min read
Company Logo
Company Logo

Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "LAMEA Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027" report has been added to's offering.

The Latin America, Middle East and Africa Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of 12.3% CAGR during the forecast period.

Increased use of the costly Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favor of off-label pharmacological therapy and non-pharmacological treatments has been the key driver for the industry. In addition, despite negative recommendations in evidence-based guidelines for general treatment, cheap corticosteroids and immunosuppressants were used to treat IPF prior to the approval of these medications.

In many countries of the region, healthcare spending per capita is rising. The desire and ability of people to spend on the health has resulted in a small increase in pharmaceutical spending.

The total rise of the healthcare industry can be ascribed to factors such as rapid economic growth and rising disposable income. Increased demand for innovative drugs/therapies for pulmonary fibrosis is likely to arise from rising pharmaceutical spending. However, high cost for the treatment of idiopathic pulmonary fibrosis is expected to discourage many people in the region to pursue healthcare goals. Smoking is becoming more common in both developed and developing countries.

In 2018, it was predicted that 9.3 percent of the 157.2 million Brazilians aged 18 and up smoked (12.1 percent males and 6.2 percent females). In the same year, 2.4 percent of adults were classified as heavy smokers (those who smoke 20 cigarettes or more per day), while 7.6 percent of adults were exposed to passive smoking at home and 6.8% at work. According to the WHO, the prevalence of smoking is higher in upper-middle-income countries than in high-income ones.

Scope of the Study
Market Segments Covered in the Report:
By Drug Type

  • Pirfenidone

  • Nintedanib

By Distribution Channel

  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Providers

By Country: Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Key Market Players

  • GNI Group Ltd.

  • Shionogi & Co., Ltd.

  • Mission Therapeutics Ltd.

  • Galapagos NV

  • FibroGen, Inc.

  • AstraZeneca PLC

  • F. Hoffmann-La Roche Ltd.

  • Bristol Myers Squibb Company

  • Boehringer Ingelheim International GmbH

  • Biogen, Inc.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Competition Analysis - Global

Chapter 4. LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type

Chapter 5. LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel

Chapter 6. LAMEA Idiopathic Pulmonary Fibrosis Market by Country

Chapter 7. Company Profiles

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting